Tofacitinib 2%

Applied topically to the affected area (typically the scalp or other hair-bearing skin) as directed by the prescriber, usually twice daily (BID). Apply a thin layer or the prescribed volume to the affected skin. Do not apply to mucous membranes, open wounds, or severely inflamed or broken skin. Wash hands after application unless the hands are the treatment area.

Apply topically as directed by the prescriber—typically a thin layer of the 2% preparation to the affected area(s) twice daily. Treatment duration is prescriber-determined; clinical response in alopecia areata may take several months to assess. Do not increase frequency or area of application without prescriber guidance.

• All dosing decisions are made by the prescribing clinician.
• Systemic absorption from topical tofacitinib is low but monitor for systemic JAK inhibitor effects with extensive application areas.

• Tofacitinib: Tofacitinib selectively inhibits JAK1 and JAK3 (with lesser effects on JAK2), blocking downstream phosphorylation of signal transducer and activator of transcription (STAT) proteins. In alopecia areata, the JAK-STAT pathway is aberrantly activated by cytokines (IFN-γ, IL-15, IL-2, IL-21) secreted by CD8+NKG2D+ T cells that breach hair follicle immune privilege. By blocking JAK1/3, tofacitinib reduces T-cell activation, inhibits IFN-γ–driven follicular epithelial damage, suppresses IL-15 and CXCL10 production, and allows restoration of anagen phase growth.

Topical tofacitinib 2% is used off-label in the prescriber-directed management of alopecia areata (AA), alopecia totalis, and alopecia universalis, as well as other inflammatory dermatoses (vitiligo, atopic dermatitis) where local JAK-STAT pathway inhibition may be beneficial. Evidence base for topical tofacitinib is derived from open-label trials and case series; efficacy is generally less robust than oral tofacitinib, with vehicle base (liposomal carriers may improve follicular penetration) influencing outcomes.

Monitoring considerations:

• Assess hair regrowth using standardized tools (e.g., SALT score) at 12-week intervals
• Monitor for local skin reactions (scalp irritation, folliculitis)
• If applied over large body surface areas, consider periodic CBC, liver function tests, and lipid panel (systemic JAK inhibitor effects)
• Monitor for secondary infection given local immunosuppressive effects

Contraindications:

• Known hypersensitivity to tofacitinib or any excipient
• Active serious infection
• Application to infected, ulcerated, or severely traumatized skin

Warnings & Precautions:

• Systemic absorption: significant application areas may produce detectable systemic tofacitinib levels with attendant immunosuppressive risks (infection, laboratory abnormalities)
• Serious infections (bacterial, viral including herpes zoster, fungal): systemic tofacitinib carries a boxed warning; topical exposure is lower but not zero
• Lipid and transaminase elevations: reported with topical use in clinical trials; periodic lipid monitoring is prudent
• Avoid in patients with active or reactivation-risk tuberculosis
• Lymphopenia and leukopenia: rare with topical use but theoretically possible with extensive application

Drug Interactions:

• Other immunosuppressants: additive immunosuppression
• Strong CYP3A4 inhibitors (ketoconazole): may increase systemic tofacitinib levels if significant absorption occurs

Common Side Effects: Scalp irritation (40% in clinical trials), folliculitis, and transient minimal elevation of total cholesterol. Systemic effects are uncommon with topical application but have been reported in trials.

Store at room temperature (15–25°C) in a tightly sealed container away from heat, humidity, and direct light. Do not freeze. Keep out of reach of children. Use within the beyond-use date established by Genesis Compounding.

What is tofacitinib 2% topical used for?

It is used off-label, under prescriber direction, primarily for alopecia areata—an autoimmune condition where immune cells attack hair follicles. By blocking JAK-STAT signaling locally, it may help restore normal hair growth cycle in affected follicles.

How effective is topical tofacitinib for alopecia areata?

Clinical evidence from open-label trials and case series suggests partial to complete hair regrowth in some patients, though response rates are variable and generally lower than oral tofacitinib. The formulation base (e.g., liposomal delivery) significantly affects follicular penetration and efficacy.

Is this FDA-approved for alopecia areata?

Tofacitinib (Xeljanz) is FDA-approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is not FDA-approved for alopecia areata or as a topical preparation. This is an off-label use in a 503A compounded preparation by Genesis Compounding.

How long before I see results?

Hair regrowth from topical JAK inhibitors may take 3–6 months of consistent application to assess. Response varies by disease severity and duration.

Are there systemic side effects from a topical application?

At typical topical doses, systemic absorption is low. However, application to large areas may produce some systemic exposure. Report any signs of infection, unusual fatigue, or abnormal lab values to your prescriber.